


## Argatroban-d<sub>3</sub>

<b>Cat. No.:</b>	HY-B0375S
<b>CAS No.:</b>	1356847-56-7
<b>Molecular Formula:</b>	C <sub>23</sub> H <sub>33</sub> D <sub>3</sub> N <sub>6</sub> O <sub>5</sub> S
<b>Molecular Weight:</b>	511.65
<b>Target:</b>	Thrombin; Isotope-Labeled Compounds
<b>Pathway:</b>	Metabolic Enzyme/Protease; Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Argatroban-d <sub>3</sub> is the deuterium labeled Argatroban. Argatroban (MD-805) is a direct, selective thrombin inhibitor.
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019;53(2):211-216.
- [2]. Kawada, T., et al., Argatroban, an attractive anticoagulant, for left heart bypass with centrifugal pump for repair of traumatic aortic rupture. *Jpn J Thorac Cardiovasc Surg*, 1999. 47(3): p. 104-9.
- [3]. Jang, I.K., et al., A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. *J Am Coll Cardiol*, 1999. 33(7): p. 1879-85.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA